Increasing Vascular Complications Depends on The Duration Disease of Having Been Diabetic Type 2
DOI:
https://doi.org/10.23851/mjs.v31i3.848Keywords:
Endothelin (ET-1), diabetes type II (T2-DM), Insulin resistance (IR), Lipid profile.Abstract
Angiopathy is a major complication in (T2-DM), Endothelin-1 (ET-1) is considered the main vasoconstrictor (a mitogenic endothelium-derived peptide is mostly, produced by endothelial cells, as well by vascular smooth muscle cells, macrophages, and other cells). Previous studies suggested a link between T2-DM and ET-1. This paper aims to study the association between Endothelin-1 (ET-1) as a marker of endothelial dysfunction and the duration disease among patients with T2-DM, and to identify the effects of obesity and insulin resistance on elevated Endothelin level. The study includes 96 patients with T2-DM, aged between (45-70) years, (56.73 ± 9.14 years) is an average duration of having T2-DM (14.541± 11.462) years, and 96 healthy control subjects, aged (45-70) years, (56.42 ± 8.74 years). We show that the excess of ET-1 level was clearly linked with the duration of T2-DM, where the plasma Endothelin level was significantly changed among the studied groups (according to their duration) (11.607 ±0.783), (13.641± 0.729), (17.736 ± 3.409), (33.816 ± 12.902), (81.165 ± 35.404), and (156.783 ± 12.671) pg/mL respectively. Plasma ET-1 levels significant is positively correlated with T2-DM (R² = 0.9711, p ≤ 0.01), with obesity, insulin resistance, age, HOMO-IR, hypertension, and HDL level (p ≤ 0.05). As a conclusion, the plasma ET-1 level was significantly elevated as long as having been T2-DM.
Downloads
References
Cecil, R.L.F., Goldman, L. and Schafer, A.I., 2012. Goldman's Cecil Medicine, Expert Consult Premium Edition--Enhanced Online Features and Print, Single Volume, 24: Goldman's Cecil Medicine (Vol. 1). Elsevier Health Sciences.
Akushevich, I., Yashkin, A.P., Kravchenko, J., Fang, F., Arbeev, K., Sloan, F. and Yashin, A.I., 2018. Identifying the causes of the changes in the prevalence patterns of diabetes in older US adults: A new trend partitioning approach. Journal of Diabetes and its Complications, 32(4), pp.362-367.
Laakso, M. and Kuusisto, J., 2014. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nature Reviews Endocrinology, 10(5), p.293.
Tanfin, Z., Robin, P., Oyeniran, C. and Breuiller-Fouché, M., 2011. Endothelin-1: physiological and pathological roles in myometrium. The international journal of biochemistry & cell biology, 43(3), pp.299-302.
De Nucci, G., Thomas, R., D'Orleans-Juste, P., Antunes, E., Walder, C., Warner, T.D. and Vane, J.R., 1988. Pressor effects of circulating Endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proceedings of the National Academy of Sciences, 85(24), pp.9797-9800.
Chatterjee, S., Khunti, K., Davies, M.J., 2017. Type 2 diabetes. Lancet 389: 2239e2251.
Clayton, D., Woo, V. and Yale, J.F., 2013. Hypoglycemia. Canadian journal of diabetes, 37, pp.S69-S71.
Wagner, O.F., Christ, G., Wojta, J., Vierhapper, H., Parzer, S., Nowotny, P.J., Schneider, B., Waldh?usl, W. and Binder, B.R., 1992. Polar secretion of Endothelin-1 by cultured endothelial cells. Journal of Biological Chemistry, 267(23), pp.16066-16068.
Fagan, T.C. and Deedwania, P.C., 1998. The cardiovascular dysmetabolic syndrome. The American journal of medicine, 105(1), pp.77S-82S.
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K. and Masaki, T., 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. nature, 332(6163), p.411.
Barham, D. and Trinder, P., 1972. An improved colour reagent for the determination of blood glucose by the oxidase system. Analyst, 97(1151), pp.142-145.
Flier, J.S., Kahn, C.R. and Roth, J., 1979. Receptors, antireceptor antibodies and mechanisms of insulin resistance. New England Journal of Medicine, 300(8), pp.413-419.
Association between Radiation Exposure and Endothelium-Dependent Vasodilation: Results from Clinical and Experimental Studies Zhu Z, et al, Journal of Vascular and Interventional Radiology, 2019.
Fossati, P. and Prencipe, L., 1982. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clinical chemistry, 28(10), pp.2077-2080.
Allain, C.C., Poon, L.S., Chan, C.S., Richmond, W.F.P.C. and Fu, P.C., 1974. Enzymatic determination of total serum cholesterol. Clinical chemistry, 20(4), pp.470-475.
Penttil?, I.M., Voutilainen, E., Laitinen, P. and Juutilainen, P., 1981. Comparison of different analytical and precipitation methods for direct estimation of serum high-density lipoprotein cholesterol. Scandinavian journal of clinical and laboratory investigation, 41(4), pp.353-360.
Devasagayam, T.P., Tarachand, U., 1987. Decreased lipid peroxidation in the rat kidney during gestation. Biochem. Biophys. Res. Commun. 145, 134-138.
Ali, H., Rustam, R., Aprilia, D., Arizal, C., Gusadri, I.B. and Utami, P.R., 2019. Upregulation of SCUBE2 expression in dyslipidemic type 2 diabetes mellitus is associated with Endothelin-1. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 13(5), pp.2869-2872.
Haak, T., Jungmann, E., Felber, A., Hillmann, U. and Usadel, K.H., 1992. Increased Plasma Levels of Endothelin in Diabetic Patients With Hypertension: An Alternative Viewpoint. American journal of hypertension, 5(3), pp.161-166.
Gursel Aka, Suleyman Buyukberbera, Alper Sevinca , H., Mehmet Turka , Mehmet Atesa, Ramazan Saria, Haluk Savlia, Ahmet Ciglib., 2001. The relation between plasma Endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus. Diabetes and Its Complications 15, 150 - 157.
Schneider, J.G., Tilly, N., Hierl, T., Sommer, U., Hamann, A., Dugi, K., Leidig-Bruckner, G. and Kasperk, C., 2002. Elevated plasma Endothelin-1 levels in diabetes mellitus. American journal of hypertension, 15(11), pp.967-972.
Güvener, N., Aytemir, K., Aks?yek, S. and Gedik, O., 1997. Plasma Endothelin-1 levels in non-insulin dependent diabetes mellitus patients with macrovascular disease. Coronary artery disease, 8(5), pp.253-258.
Bertello, P., Veglio, F., Pinna, G., Gurioli, L., Molino, P., Alban, S. and Chiandussi, L., 1994. Plasma Endothelin in NIDDM patients with and without complications. Diabetes Care, 17(6), pp.574-577.
Veglio, F., Bertello, P., Pinna, G., Mulatero, P., Rossi, A., Gurioli, L., Panarelli, M. and Chiandussi, L., 1993. Plasma Endothelin in essential hypertension and diabetes mellitus. Journal of human hypertension, 7(4), pp.321-325.
Bertello, P., Veglio, F., Pinna, G., Gurioli, L., Molino, P., Alban, S. and Chiandussi, L., 1994. Plasma Endothelin in NIDDM patients with and without complications. Diabetes Care, 17(6), pp.574-577.
Takahashi, K., Ghatei, M.A., Lam, H.C., O'halloran, D.J. and Bloom, S.R., 1990. Elevated plasma Endothelin in patients with diabetes mellitus. Diabetologia, 33(5), pp.306-310.
Ahlborg, G., Shemyakin, A., B?hm, F., Gonon, A. and Pernow, J., 2007. Dual Endothelin receptor blockade acutely improves insulin sensitivity in obese patients with insulin resistance and coronary artery disease. Diabetes Care, 30(3), pp.591-596.
Gaboury, C.L., Simonson, D.C., Seely, E.W., Hollenberg, N.K. and Williams, G.H., 1994. Relation of pressor responsiveness to angiotensin II and insulin resistance in hypertension. The Journal of clinical investigation, 94(6), pp.2295-2300.
Ishibashi, K.I., Imamura, T., Sharma, P.M., Huang, J., Ugi, S. and Olefsky, J.M., 2001. Chronic Endothelin-1 treatment leads to heterologous desensitization of insulin signaling in 3T3-L1 adipocytes. The Journal of clinical investigation, 107(9), pp.1193-1202.
Shaw, S.G. and Boden, P.J., 2005. Insulin resistance, obesity and the metabolic syndrome. Is there a therapeutic role for Endothelin-1 antagonists?. Current vascular pharmacology, 3(4), pp.359-363.
Wheatcroft, S.B., Williams, I.L., Shah, A.M. and Kearney, M.T., 2003. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabetic Medicine, 20(4), pp.255-268.
Seligman, B.G., Biolo, A.N.D.R.E.I.A., Polanczyk, C.A., Gross, J.L. and Clausell, N., 2000. Increased plasma levels of Endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care, 23(9), pp.1395-1400.
Cuchel, M. and Rader, D.J., 2006. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?. Circulation, 113(21), pp.2548-2555.
Njajou, O.T., Kanaya, A.M., Holvoet, P., Connelly, S., Strotmeyer, E.S., Harris, T.B., Cummings, S.R. and Hsueh, W.C., 2009. Association between oxidized LDL, obesity and type 2 diabetes in a population?based cohort, the Health, Aging and Body Composition Study. Diabetes/metabolism research and reviews, 25(8), pp.733-739.
Steinberg, D., 1997. Low density lipoprotein oxidation and its pathobiological significance. Journal of Biological Chemistry, 272(34), pp.20963-20966.
Boulanger, C.M., Tanner, F.C., Bea, M.L., Hahn, A.W., Werner, A. and Lüscher, T.F., 1992. Oxidized low density lipoproteins induce mRNA expression and release of Endothelin from human and porcine endothelium. Circulation Research, 70(6), pp.1191-1197.
Downloads
Key Dates
Published
Issue
Section
License
(Starting May 5, 2024) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
How to Cite
